A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin
Hellwig et al.
, A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin
, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248
Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infections showing significantly lower incidence of COVID-19 cases.
This study is excluded in the after exclusion results of meta
not a typical trial, analysis of African countries that used or did not use ivermectin prophylaxis for parasitic infections.
risk of case, 78.0% lower, RR 0.22, p < 0.02, African countries, PCTI vs. no PCT, relative cases per capita.
risk of case, 80.0% lower, RR 0.20, p < 0.001, worldwide, PCTI vs. no PCT, relative cases per capita.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hellwig et al., 28 Nov 2020, retrospective, ecological study, multiple countries, peer-reviewed, 2 authors, dosage 200μg/kg, dose varied, typically 150-200μg/kg.
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
International Journal of Antimicrobial Agents 57 (2021) 106248
Contents lists available at ScienceDirect
International Journal of Antimicrobial Agents
journal homepage: www.elsevier.com/locate/ijantimicag
A COVID-19 prophylaxis? Lower incidence associated with
prophylactic administration of ivermectin
Martin D. Hellwig a,∗, Anabela Maia b
Plymouth State University, 17 High Street, Plymouth, NH, USA
Rhode Island College, 600 Mount Pleasant Avenue, Providence, RI, USA
a r t i c l e
i n f o
Received 20 June 2020
Accepted 22 November 2020
Mass drug administration
a b s t r a c t
As COVID-19 (coronavirus disease 2019) continues to rapidly spread throughout the world, the incidence
varies greatly among different countries. These differences raise the question whether nations with a
lower incidence share any medical commonalities that could be used not only to explain that lower incidence but also to provide guidance for potential treatments elsewhere. Such a treatment would be particularly valuable if it could be used as a prophylactic against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission, thereby effectively slowing the spread of the disease while we await
the wide availability of safe and effective vaccines. Here, we show that countries with routine mass drug
administration of prophylactic chemotherapy including ivermectin have a signiﬁcantly lower incidence of
COVID-19. Prophylactic use of ivermectin against parasitic infections is most common in Africa and we
hence show that the reported correlation is highly signiﬁcant both when compared among African nations as well as in a worldwide context. We surmise that this may be connected to ivermectin’s ability
to inhibit SARS-CoV-2 replication, which likely leads to lower infection rates. However, other pathways
must exist to explain the persistence of such an inhibitory effect after serum levels of ivermectin have
declined. It is suggested that ivermectin be evaluated for potential off-label prophylactic use in certain
cases to help bridge the time until a safe and effective vaccine becomes available.
© 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.